Personalized treatment for rifampicin-resistant TB
Treatments studied
Part of Infections, Lungs & breathing clinical trials.
This trial tests a personalized treatment approach for people with rifampicin-resistant TB that is still sensitive to fluoroquinolones. It aims to find the best combination of medicines based on your specific TB profile.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a type of TB that is resistant to rifampicin but not to fluoroquinolones, confirmed by a lab test.
- You are 14 years or older.
- You are willing to have home visits and phone calls, and to tell the study team if you move.
- You can provide consent (or have a parent or guardian do so if you are a minor).
- Your liver, kidney, and blood counts are within safe ranges (checked by blood tests).
- If you have HIV, your CD4 count is at least 50 and you are on or starting dolutegravir-based HIV treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a shorter course of three drugs (bedaquiline, moxifloxacin, and pyrazinamide) for people with newly diagnosed, drug-sensitive TB. It aims to see how quickly the drugs kill the bacteria in the first few days of treatment.
This study is testing new combinations of drugs to treat tuberculosis (TB) in the lungs. It aims to find a more effective and shorter treatment, and you may benefit from receiving these new drugs while helping advance TB research.
This trial studies whether a rifapentine-based TB regimen can work just as well while shortening treatment time. It’s for people with rifampicin-sensitive, smear-positive lung tuberculosis.
This trial tests whether using results from a detailed sputum (phlegm) test to tailor treatment improves outcomes in people with drug-resistant (rifampicin-resistant) pulmonary TB. It may help you get the most appropriate regimen based on your specific test results.
This trial tests a combination of drugs for people with active tuberculosis who have not been treated before. It aims to find a better way to treat TB, even if the bacteria are resistant to some drugs.
This trial tests a shorter treatment for drug-resistant tuberculosis (TB) using the medicine Pretomanid. It aims to find a more manageable cure for people whose TB does not respond to the standard first-line drug, rifampicin.
Hear when a new Tuberculosis, Pulmonary trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.